ClinicalTrials.gg
CompletedNCT00821327Updated Oct 25, 2016Results posted

Gemzar, Cisp, Sunitinib Urothelial Ca

A Phase 2 interventional study of Gemcitabine, Cisplatin, Sunitinib in Urothelial Cancer, sponsored by US Oncology Research. Completed at 48 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-10-25.

Sponsored by US Oncology Research (part of Sarah Cannon Research Institute) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of this nonrandomized Phase II study is to evaluate the objective response rate (ORR, CR+PR) in patients with advanced/metastatic UC treated with the combination of gemcitabine, cisplatin, and sunitinib.

Read the detailed description

Given the strong preclinical rationale for targeting angiogenesis in urothelial carcinoma (UC), the evidence supporting co-targeting of VEGFR2 and PDGF, the safety and efficacy of single-agent sunitinib in patients with UC, and preclinical evidence of synergy with the combination of sunitinib and cisplatin, the evaluation of sunitinib in combination with gemcitabine plus cisplatin in previously untreated patients with metastatic UC is warranted.

02

Conditions studied

  • Urothelial Cancer
03

In context

Lead sponsor

US Oncology Research is the lead sponsor of 29 studies on the registry; 1 is open to participants now.

First submitted before US Oncology Research became part of Sarah Cannon Research Institute.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has histological documentation of diagnosis of transitional cell carcinoma (TCC) of the bladder, urethra, ureter, or renal pelvis (histology may be mixed, but still requires a component of TCC; only)
  2. Has unresectable or disease
  3. Has a Performance Status greater than or equal 60 percent
  4. Is 18 years of age or older
  5. Has laboratory values as defined by the protocol
  6. Has resolution of all acute toxic effects of prior chemotherapy or radiotherapy or surgical procedures to (v3.0) Grade less than or equal to 1
  7. Has normal cardiac function as evidenced by a greater than or equal to 50 percent, as determined by multiple gated acquisition (MUGA) scan or an echocardiogram (ECHO). The same method must be used throughout the study to evaluate LVEF.
  8. Has a negative serum pregnancy test within 7 calendar days prior to registration (female patients of [not surgically sterilized and between menarche and 1 year ])
  9. Is not currently breastfeeding
  10. If fertile, patient (male or female) has agreed to use an acceptable method of to avoid pregnancy for the duration of the study and for a period of 3 months thereafter.
  11. Has signed a Patient Form, Has signed a Patient Authorization Form

Exclusion criteria

Exclusion Criteria:

  1. Has had prior treatment with systemic chemotherapy (prior intravesical therapy is permitted)
  2. Has had major surgery or radiation therapy within 4 weeks of starting the study treatment
  3. Has had (Version 3.0) Grade 3-4 hemorrhage within 4 weeks of starting the study treatment
  4. Has a history of or known spinal cord compression, or carcinomatous meningitis, or evidence of symptomatic brain or on screening CT or MRI scan. However treated, stable and asymptomatic are allowed.
  5. Has had any of the following within the 6 months prior to study drug administration: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or , or pulmonary embolism
  6. Has ongoing cardiac dysrhythmias of NCI CTCAE (Version 3.0) Grade 2
  7. Has prolonged on baseline
  8. Has uncontrolled hypertension (grater than 150/100 mm Hg despite optimal medical therapy)
  9. Has pre-existing thyroid abnormality with thyroid function that cannot be maintained in the normal range with medication
  10. Has known (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness or other active infection
  11. Is receiving concomitant use of any other drugs or has received such drug within 28 days prior to registration
  12. Is receiving concurrent treatment on another clinical trial, including supportive care
  13. Has ongoing treatment with therapeutic doses of warfarin (low dose warfarin up to 2 mg PO daily for thromboembolic prophylaxis allowed). Patients on warfarin (greater than 2mg) for thrombosis must be switched to low molecular weight heparin (ie, Lovenox), prior to registration for protocol therapy.
  14. Is currently taking drugs having proarrhythmic potential (terfenadine, quinidine, procainamide, disopyramide, sotalol, probucol, bepridil, haloperidol, risperidone, indapamide and flecainide) within 7 days prior to Day 1 of Cycle 1 (dosing) (and throughout study)
  15. Is currently on inhibitors (see Section 5) within 7 days prior to Day 1 of Cycle 1 (dosing), with the exception of amiodarone, which should be discontinued within 6 months prior to Day 1 of Cycle 1 (dosing)
  16. Is currently on CYP3A4 inducers (see Section 5) within 14 days prior to Day 1 of Cycle 1 (dosing)
  17. Has been taking herbal or alternative medications within the past 7 days or refuses to discontinue the use of herbal or alternative therapies within 7 days prior to Day 1 of Cycle 1 (dosing)
  18. Has a serious uncontrolled intercurrent medical or psychiatric illness, including serious infection
  19. Has a history of other within the last 5 years (except cured basal cell carcinoma of skin and carcinoma in situ of uterine cervix), which could affect the diagnosis or assessment of any of the study drugs.
  20. Is a pregnant or nursing woman. Patients must be surgically sterile or be , or must agree to use effective during the period of therapy. The definition of effective contraception will be based on the judgment of the Study Investigator or Treating Physician. Male patients must be surgically sterile or agree to use effective contraception.

Is unable to comply with requirements of study

Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Study Arm

    Gemcitabine, Cisplatin, Sunitinib

    Drug: Gemcitabine, Cisplatin, Sunitinib

Interventions

  • DrugGemcitabine, Cisplatin, Sunitinib

    Drug pages: Gemcitabine · Cisplatin · Sunitinib

    Patients will receive gemcitabine 800 mg/m2 IV (Days 1 and 8), cisplatin 60 mg/m2 IV (Day 1), and sunitinib 37.5 mg PO daily (Days 1-14) of each 21-day cycle. 2. One cycle of treatment is defined as 21 days (3 weeks). Restaging studies will be performed after every 3 cycles of therapy. 3. Successive cycles will be initiated every 3 weeks, and will be continued through 6 cycles unless a patient shows evidence of disease progression or intolerable toxicity.

    Also known as: Gemzar, Sutent

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR, CR+PR) in Patients With Advanced/Metastatic UC Treated With the Combination of Gemcitabine, Cisplatin, and Sunitinib.

    Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.

    Time frame: 2 years

Secondary outcomes

  1. Progression-free Survival

    PFS is measured from the date of randomization to the date of first documented disease progression or date of death, whichever comes first. If a patient neither progresses nor dies, this patient will be censored at last contact date. Progression (PD) is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions.

    Time frame: 2 years

  2. Ovarall Survival (OS)

    OS is measured from the date of randomization to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the last contact date.

    Time frame: 2 years

07

Results

Posted Mar 2, 2016

Participant flow

Participant flow — Overall Study
MilestoneStudy Arm: Advanced/Metastatic UC
Started36
Completed1
Not completed35
Withdrew: Adverse event13
Withdrew: Patient request1
Withdrew: Investigator request2
Withdrew: Sponsor request1
Withdrew: Disease progression13
Withdrew: Other/unknown5

Outcome measures

PrimaryObjective Response Rate (ORR, CR+PR) in Patients With Advanced/Metastatic UC Treated With the Combination of Gemcitabine, Cisplatin, and Sunitinib.

Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LD.

Time frame:
2 years
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR, CR+PR) in Patients With Advanced/Metastatic UC Treated With the Combination of Gemcitabine, Cisplatin, and Sunitinib.
Percentage of participantsStudy Arm: Advanced/Metastatic UC
Objective Response Rate (ORR, CR+PR) in Patients With Advanced/Metastatic UC Treated With the Combination of Gemcitabine, Cisplatin, and Sunitinib.48.5 (30.8 to 66.5)
SecondaryProgression-free Survival

PFS is measured from the date of randomization to the date of first documented disease progression or date of death, whichever comes first. If a patient neither progresses nor dies, this patient will be censored at last contact date. Progression (PD) is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of 1 or more new lesions.

Time frame:
2 years
Reported as:
Median · Month
Progression-free Survival
MonthStudy Arm: Advanced/Metastatic UC
Progression-free Survival8.0 (7.0 to 14.0)
SecondaryOvarall Survival (OS)

OS is measured from the date of randomization to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the last contact date.

Time frame:
2 years
Reported as:
Median · months
Ovarall Survival (OS)
monthsStudy Arm: Advanced/Metastatic UC
Ovarall Survival (OS)13.8 (10.1 to 22.9)

Adverse events

Collected over During the whole treatment period, up to 30 days following last dose.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Study Arm: Advanced/Metastatic UC—7/33 (21.2%)32/33 (97%)
Most frequent serious events
Most frequent serious events
EventStudy Arm: Advanced/Metastatic UC
ANEMIABlood and lymphatic system disorders1/33
BLOOD PRESSURE INCREASEDBlood and lymphatic system disorders1/33
CELLULITISInfections and infestations1/33
HEMOGLOBIN DECREASEDBlood and lymphatic system disorders1/33
LYMPHADENOPATHY THORACICBlood and lymphatic system disorders1/33
NEUTROPENIABlood and lymphatic system disorders1/33
PANCREATITISInfections and infestations1/33
THROMBOCYTOPENIABlood and lymphatic system disorders1/33
Most frequent other events
Showing 10 of 35
Most frequent other events
EventStudy Arm: Advanced/Metastatic UC
NEUTROPENIABlood and lymphatic system disorders30/33
THROMBOCYTOPENIABlood and lymphatic system disorders24/33
ANEMIABlood and lymphatic system disorders22/33
FATIGUEGeneral disorders18/33
NAUSEAGastrointestinal disorders16/33
LEUCOPENIABlood and lymphatic system disorders10/33
CONSTIPATIONGastrointestinal disorders9/33
GASTROESOPHAGEAL REFLUXGastrointestinal disorders9/33
ANOREXIAGastrointestinal disorders8/33
SHORTNESS OF BREATHRespiratory, thoracic and mediastinal disorders7/33

Baseline characteristics

Age, Continuous
Age, Continuous(years)Study Arm: Advanced/Metastatic UC
Mean64.0 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)Study Arm: Advanced/Metastatic UC
Female8
Male28
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Study Arm: Advanced/Metastatic UC
Caucasian32
Hispanic2
Asian1
Black1
Region of Enrollment
Region of Enrollment(participants)Study Arm: Advanced/Metastatic UC
United States36
08

Study locations

48 sites
  • Arizona Oncology Associates
    Tucson, Arizona 85704, United States
  • Advanced Medical Specialties
    Miami, Florida 33176, United States
  • Florida Cancer Institute - New Hope
    New Port Richey, Florida 34655, United States
  • Cancer Centers of Florida, P.A.
    Ocoee, Florida 34761, United States
  • Hematology Oncology Associates of Illinois
    Chicago, Illinois 60611, United States
  • Cancer Care & Hematology Specialists of Chicagoland
    Niles, Illinois 60714, United States
  • Central Indiana Cancer Centers
    Indianapolis, Indiana 46227, United States
  • Alliance Hematology Oncology PA.
    Westminster, Maryland 21157, United States
  • Minnesota Oncology Hematology, P.A.
    Minneapolis, Minnesota 55404, United States
  • Missouri Cancer Associates
    Columbia, Missouri 65201, United States
  • Arch Medical Services, Inc.
    St. Louiis, Missouri 63141, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89169, United States
  • Hematology-Oncology Associates of Northern NJ, PA
    Morristown, New Jersey 07962, United States
  • New Mexico Cancer Care Associates
    Santa Fe, New Mexico 87505, United States
  • New York Oncology Hematology, P.C.
    Albany, New York 12206, United States
  • Raleigh Hematology Oncology Associates
    Raleigh, North Carolina 27607, United States
  • Willamette Valley Cancer Center
    Springfield, Oregon 97477, United States
  • Medical Oncology Associates of Wyoming Valley, PC
    Kingston, Pennsylvania 18704, United States
  • Cancer Centers of the Carolinas
    Greenville, South Carolina 29605, United States
  • Texas Cancer Center - Abilene
    Abilene, Texas 79606, United States
  • Texas Oncology, P.A. -Amarillo
    Amarillo, Texas 79106, United States
  • Texas Cancer Center
    Arlington, Texas 76014, United States
  • Texas Oncology - Round Rock Cancer Center
    Austin, Texas 78731, United States
  • Mamie McFaddin Ward Cancer Center, Texas Oncology
    Beaumont, Texas 77702, United States
  • Texas Oncology, P.A. - Bedford
    Bedford, Texas 76022, United States
  • Texas Oncology
    Dallas, Texas 75230, United States
  • Texas Oncology/Methodist Charlton Cancer Ctr.
    Dallas, Texas 75237, United States
  • Texas Oncology, P.A.
    Dallas, Texas 75246, United States
  • Texas Cancer Center
    Denton, Texas 76210, United States
  • El Paso Cancer Treatment Center - East
    El Paso, Texas 79915, United States
  • Texas Oncology
    Fort Worth, Texas 76104, United States
  • Texas Oncology
    Garland, Texas 75042-5788, United States
  • Longview Cancer Center
    Longview, Texas 75601, United States
  • South Texas Cancer Center
    McAllen, Texas 78503, United States
  • Texas Oncology, PA, Allison Cancer Center
    Midland, Texas 79701, United States
  • Cancer Care Centers of South Texas
    San Antonio, Texas 78217, United States
  • Cancer Care Centers of South Texas-HOAST
    San Antonio, Texas 78229, United States
  • Texas Cancer Center - Sherman
    Sherman, Texas 75090, United States
  • Texas Oncology Cancer Center - Sugar Land
    Sugar Land, Texas 77479, United States
  • Tyler Cancer Center
    Tyler, Texas 75702, United States
  • Texas Oncology Cancer Care and Research Center
    Waco, Texas 76712, United States
  • Deke Slayton Cancer Center
    Webster, Texas 77598, United States
  • Virginia Oncology Associates
    Norfolk, Virginia 23502, United States
  • Oncology & Hematology Associates of Southwest Virginia, Inc.
    Salem, Virginia 24153, United States
  • Highline Medical Oncology
    Burien, Washington 98166, United States
  • Pudget Sound Cancer Center
    Edmonds, Washington 98026, United States
  • Cancer Care Northwest
    Spokane, Washington 99202, United States
  • Northwest Cancer Specialists, PC
    Vancouver, Washington 98684, United States
09

References and documents

Publications

  • Galsky MD, Hahn NM, Powles T, Hellerstedt BA, Lerner SP, Gardner TA, Yu M, O'Rourke M, Vogelzang NJ, Kocs D, McKenney SA, Melnyk AM Jr, Hutson TE, Rauch M, Wang Y, Asmar L, Sonpavde G. Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. Clin Genitourin Cancer. 2013 Jun;11(2):175-81. doi: 10.1016/j.clgc.2012.10.001. Epub 2012 Dec 8. PubMed 23228446 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2016, 3 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2009
First posted
Jan 13, 2009
Start
Aug 2008
Primary completionActual
Aug 2012
CompletionActual
Aug 2012
Results first posted
Mar 2, 2016
Last update
Oct 25, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00821327
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Jan 13, 2009
Start date
Aug 2008
Primary completion
Aug 2012
Completion
Aug 2012
Results posted
Mar 2, 2016
Last update
Oct 25, 2016

Study contacts

Guru Sonpavde, MD
principal investigator · US Oncology
Thomas E Hutson, DO
principal investigator · US Oncology

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gemcitabine · Cisplatin · Sunitinib

Start the discussion